Ann: Volpara DENSE trial results published, page-14

First 14 Last

Share
Profile

Follow
prosperity

9,276 Posts.

893

29/11/19

14:40

Post #: 41711369
Share

Originally posted by TheInvestor2: ↑

the Dense result was positive however like any other study. it do not constitute money in the door.

However, it does provide a licence to hunt, particularly in Europe.

The next announcement of interest will be the FDA and the release of national standards in the US. It should be remembered that a majority of US states already mandate some degree of reporting of breast density, however the requirements vary across states.

the drivers of growth in the VHT business have not changed in the US they remain:-

1) hitting the 27% target and increasing coverage over time- this may also include further acquisitions.

2) increasing the ARR - this has the potential to be the game changer - if fee per service can be increased from currently just over 1$ us to 10$ us , it will make VHT very profitable business. The ability to increase this fee will be the integration of the VHT business with the US business and repackaging as a new product (ie1+1=3) . This repackaging provides the opportunity to reprice upwards.

3) Whilst the focus has been on the US, the Dense result will influence change particularly in Europe and will hopefully result in growth of their business there.

if management can execute successfully, I expect this stock to double in value in the next 3to4 years.

However, like any other stock it will go up and down over this period - it is never a straight line up.

best of luck to all

RegardS

Expand

Dog stocks fluctuate in a downward direction, like today.

VHT Price at posting: $1.80 Sentiment: Sell Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

TYX

Tyranna wraps up lithium drilling in Angola; says looking for other projects with different metals

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

First 14 Last

Add VHT (ASX) to my watchlist

Ann: Volpara DENSE trial results published, page-14

Top Stories

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Cyclone signs MOU with Vale for development of Iron Bear play

Tyranna wraps up lithium drilling in Angola; says looking for other projects with different metals

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Banshee's historic trenches prove rich in antimony and gold for GDM

Featured News